GlassScriptPhysician profile
Jibran Khan
NPI 1902803935
$2,737.87
in general payments reported to CMS, 2019-2025
28 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $303 · 2021: $213 · 2022: $397 · 2023: $356 · 2024: $417 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $433.49 | 2019-2021 | |
| Mylan Specialty L.P. | $417.36 | 2019-2024 | Yupelri |
| Abbvie INC. | $344.33 | 2022-2025 | |
| Novo Nordisk INC | $232.36 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $206.14 | 2019-2025 | Kisunla, Mounjaro |
| Exact Sciences Corporation | $143.71 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $143.58 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.56 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.48 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $78.02 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $72.83 | 2022-2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $72.40 | 2024-2025 | Airsupra |
| Paratek Pharmaceuticals, INC. | $44.16 | 2023-2024 | Nuzyra |
| Davol INC. | $43.49 | 2024 | Channel Drain |
| Xeris Pharmaceuticals, INC. | $39.75 | 2024-2025 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $27.09 | 2024 | Lucemyra |
| Viatris Specialty LLC | $24.12 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $22.46 | 2025 | Trelegy Ellipta |
| Allergan, INC. | $22.11 | 2019-2020 | |
| Octapharma USA, INC. | $19.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2023 | Trintellix |
| Nestle Healthcare Nutrition INC. | $17.13 | 2020 | |
| Currax Pharmaceuticals LLC | $16.98 | 2024 | Contrave |
| Dexcom, INC. | $16.16 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $15.48 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $14.97 | 2022 | |
| Genzyme Corporation | $14.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jibran Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.